New radiotherapy method tested in breast cancer that has spread to the brain
Tests a new radiation method in adults with breast cancer spread to the brain.
Key facts
- Who runs it
- Imperial College London
- Where
- London and Oxford, United KingdomSee the 2 sites
- Trial code
- Registry title
- BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
- Status
- Recruiting
- People taking part
- 42 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- DE-iPTV
- Record updated
- 8 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the United Kingdom with breast cancer that has spread to the brain. Their doctor must think whole-brain radiotherapy is the usual treatment outside the trial.
- Age
- 16 years and older, up to 100 years
- Sex
- All sexes can join
- Disease stage
- Breast cancer confirmed by tissue test, with brain metastases seen on MRI. Daily activity level (ECOG performance status) of 0, 1 or 2. Life expectancy from disease outside the brain of more than 3 months.
- Earlier treatment
- No earlier radiotherapy to the whole or part of the brain. Earlier surgery or stereotactic radiosurgery (SRS) is acceptable.
Main reasons for not taking part
- Cancer spread to the membranes around the brain (leptomeningeal disease)
- More than 15 brain metastases, or a miliary pattern, or cystic metastases
- Plan for hippocampal-sparing whole brain radiotherapy
- Pregnant or nursing women
- Cannot have a brain MRI, or known allergy to gadolinium
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up
- Adult (aged 16+) patients, resident in the United Kingdom
- Histologically confirmed primary breast cancer with brain metastases on MRI imaging
- The treating oncologist considers whole-brain radiotherapy to be the most suitable treatment outside of the trial
- Eastern Cooperative Oncology Group Performance status 0, 1 or 2
- Able to respond to question about their quality of life, symptoms, and side effects remotely (via telephone assessments
- Life expectancy from extra-cranial disease >3 months
Who cannot take part
- Previous whole or partial brain radiotherapy (previous surgery or SRS is acceptable)
- Plan for hippocampal-sparing whole brain radiotherapy
- Leptomeningeal disease
- Unable to complete a brain MRI and/or known allergy to gadolinium
- "Miliary" pattern of metastases: patients with over 15 metastases are excluded (clinician-based assessment)
- Cystic metastases
- Unable to give informed consent
- Prognosis less than 3 months
- Pregnant or nursing women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 100 years old?
Where in United Kingdom
- Imperial College LondonLondon, United KingdomContact: Lillie Pakzad Shahabi, BSc MScTaking people
- University of Oxford Cancer and Haematology Centre | Churchill Hospital Headington, Oxford,Oxford, United KingdomContact: Oxford Cancer TrialsTaking people
About the trial
What the trial wants to find out
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast cancer has spread to the brain (brain metastases) at 8 weeks post enrolling into the study.
Read full original descriptionShow less
The main questions that have been set out to to answer are:
* Is it possible to deliver the novel radiotherapy approach, DE-iPTV? * Is it possible to measure health -related quality of life? * What impact does the novel radiotherapy approach have on: patient's quality of life, control of the brain metastasis (control of the lesion) and steroid use?
Participants will:
* Receive 5 doses of radiotherapy * Complete weekly quality of life (EQ-5D) assessments and medication (steroid) diaries (via telephone/ postal) until 12 weeks post enrolment * Be reviewed in clinic with up-to-date MRI scans at 8, 12 and 24 weeks post-enrolment * Complete a more detailed HRQoL panel of assessments will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks post enrolment.
The group in the trial
- DE-iPTV radiotherapyTreatment being tested
Patients will undergo a radiotherapy planning scan, and an upto date MRI brain with contrast. Patients will receive 5 fractions of DE-iPTV radiotherapy over 1 week.
Treatment: DE-iPTV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- BEAT-Breast - Improving Outcomes for Breast Cancer Patients With Brain Metastases: a Pilot Nonrandomised Single Arm Phase 2 Clinical Trial in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy
- Plain-language title
- New radiotherapy method tested in breast cancer that has spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06611306, who can take part
- Record updated
- 8 October 2026